Closing of Series B1 Financing and Restructuring of Board of Directors Sets Stage for Future Financing and Clinical Study Strategy for Next Generation Point-Guard Full Brain Stroke Protection.

Point-Guard Protected™ Safeguard the Brain, Treat the Heart.

Transverse Medical, Inc., developer of the POINT-GUARD™ Cerebral Embolic Protection medical device to protect the patient from stroke during Transcatheter Aortic Valve Replacement (TAVR) has reorganized the Board of Directors following the recent closing of a Series B1 financing.

Transverse Medical is pleased to announce the appointment of David C. Blowers to the Board of Directors. Eric Goslau will remain as President & CEO and a member of the Board. Carl St. Bernard has been reinstated as an independent member to the Board of Directors; Mr. St. Bernard first joined the company in March of 2021 and has served as an Executive Advisor and Board Director. Rahul P. Sharma, MD, has joined the Board of Directors as an independent member and will also Chair the Medical Advisory Board.

Mr. David C. Blowers is an experienced wealth management and finance professional, board director, C-Suite Executive, and currently serves as Vice Chairman of Northern Trust. In addition to his Board Role, Mr. Blowers will serve as the company’s Corporate Secretary. Mr. Blowers holds an MBA with a concentration in Finance from the Kellogg School of Northwestern University and completed his Bachelor of Arts degree in Government from Lawrence University.

Mr. Carl St. Bernard is currently the President & Chief Executive Officer of Alta Biomaterials. Prior to joining Alta Biomaterials, Mr. St. Bernard was President & Chief Executive Officer of Tryton Medical, a start-up interventional medicine company that was successfully exited in 2019. Mr. St. Bernard has over 30 years of experience in the life sciences field and medical device markets. Mr. St. Bernard has broad leadership experience and has held senior executive positions at healthcare leaders such as Johnson & Johnson, Abbott Labs, and GE Healthcare.

Dr. Rahul P. Sharma, MBBS, FRACP is the Director of Structural Interventions at Stanford Healthcare, Associate Director of the Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine at Stanford University. In addition to Dr. Sharma’s clinical expertise in structural heart and cerebral embolic protection, he is Co-Founder and Board Member of Synchron, Inc. the endovascular brain-computer interface company, and serves as Chief Medical Officer of Egnite, a company developing artificial intelligence for cardiovascular medicine.

Dr. Sharma remarked, “I’m looking forward to joining the Board and contributing my clinical expertise to the success of the next generation POINT-GUARD™ and the company’s future clinical plans and strategy. The Point-Guard solution for Full Brain Protection is critically needed to address the risk of Stroke during TAVR and which fully meets the success criteria for cerebral embolic protection.”

“I’m impressed with our Operating Team and their ability to persevere and drive the Point-Guard program forward. We are grateful for our investors that have continued to support and rally behind the company and the Point-Guard solution for full brain protection. The Leadership Team and our impressive Medical Advisory members are passionate and committed to our company Mission. Transverse Medical is now recharged, primed, and ready to achieve key milestones,” said Eric Goslau, President & CEO.

About POINT-GUARD™ and Transverse Medical, Inc.

Transverse Medical is an early-stage medical device company focused on the development of the POINT-GUARD™ Cerebral Embolic Protection medical device for use during Transcatheter Aortic Valve Replacements (TAVR) to protect patients from embolic debris (particles) that are dislodged and released (debris shower) into the cerebral blood flow that could lead to periprocedural stroke as a result of the TAVR procedure.

The next generation Point-Guard is a breakthrough advancement for complete Cerebral Embolic Protection of the brain and designed with operator ease of use and ability to accommodate variable arch anatomies with low interference and full aortic arch stabilization.

Notice: The POINT-GUARD™ is currently in development and has not been approved for human use by the US FDA or any regulatory authority.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402536166/en/